文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

肿瘤门诊患者静脉血栓栓塞症ONKOTEV风险预测模型的验证

Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer.
PubMed 文献 · JAMA Netw Open · 2023-02-01
一句话结论ONKOTEV评分在独立肿瘤门诊人群中验证可用于癌症相关血栓预测,作者认为可纳入实践作为一级预防决策工具。

ONKOTEV-2为在意大利、德国、英国3个欧洲中心开展的非干预性预后研究,前瞻性纳入425例接受积极治疗、组织学确诊实体瘤的门诊患者,基线计算ONKOTEV评分(Khorana评分>2、转移性疾病、血管或淋巴管压迫、既往VTE事件4项变量)并随访检测血栓栓塞事件。主要终点为VTE(深静脉血栓和肺栓塞)发生率。6个月VTE累积发生率在ONKOTEV评分0、1、2、>2分组分别为2.6%(95%CI 0.7%-6.9%)、9.1%(95%CI 5.8%-13.2%)、32.3%(95%CI 21.0%-44.1%)、19.3%(95%CI 2.5%-48.0%),P<.001;3、6、12个月时间依赖AUC分别为70.1%(95%CI 62.1%-78.7%)、72.9%(95%CI 65.6%-79.1%)、72.2%(95%CI 65.2%-77.3%)。作者认为该评分在独立人群中验证为新型癌症相关血栓预测模型,可纳入实践和临床干预试验作为一级预防决策工具。

要点

  • ONKOTEV评分含4项变量:Khorana评分>2、转移性疾病、血管或淋巴管压迫、既往VTE事件。
  • 6个月VTE累积发生率:评分0分2.6%(95%CI 0.7%-6.9%),1分9.1%(95%CI 5.8%-13.2%),2分32.3%(95%CI 21.0%-44.1%),>2分19.3%(95%CI 2.5%-48.0%),P<.001。
  • 时间依赖AUC:3个月70.1%(95%CI 62.1%-78.7%),6个月72.9%(95%CI 65.6%-79.1%),12个月72.2%(95%CI 65.2%-77.3%)。
  • 现行国际指南推荐Khorana评分≥2分的中高危患者接受一级预防。
  • 作者认为ONKOTEV评分可作为一级预防决策工具纳入实践和临床干预试验。

适用人群与场景

  • 3个欧洲中心(意大利、德国、英国)前瞻性队列中425例门诊患者,组织学确诊实体瘤并接受积极治疗。

诊断标准与关键阈值

  • ONKOTEV评分由4项变量组成:Khorana评分>2、转移性疾病、血管或淋巴管压迫、既往VTE事件。
  • 现行国际指南以Khorana评分≥2分作为中高危VTE、推荐一级预防的界值。

研究设计与关键结果

  • ONKOTEV-2为非干预性预后研究,在意大利、德国、英国3个欧洲中心前瞻性纳入425例接受积极治疗、组织学确诊实体瘤的门诊患者,总研究时长52个月,入组期28个月(2015年5月1日至2017年9月30日),总随访24个月(数据截至2019年9月30日),统计分析于2019年10月进行。
  • 425例患者中女性242例(56.9%),中位年龄61岁(范围20-92岁)。
  • 主要终点为VTE(包括深静脉血栓和肺栓塞)发生率。
  • 6个月VTE累积发生率在ONKOTEV评分0、1、2、>2分组分别为2.6%(95%CI 0.7%-6.9%)、9.1%(95%CI 5.8%-13.2%)、32.3%(95%CI 21.0%-44.1%)、19.3%(95%CI 2.5%-48.0%),P<.001。
  • 时间依赖AUC在3、6、12个月分别为70.1%(95%CI 62.1%-78.7%)、72.9%(95%CI 65.6%-79.1%)、72.2%(95%CI 65.2%-77.3%)。

证据类型、等级与局限

  • 证据类型:非干预性预后研究(前瞻性队列验证研究)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,ONKOTEV评分已在独立研究人群中验证为新型癌症相关血栓预测模型,可纳入实践和临床干预试验作为一级预防决策工具。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The assessment of the risk of venous thromboembolism (VTE) among outpatients with cancer represents an unsolved topic. Current international guidelines recommend primary prophylaxis for patients at intermediate to high risk of VTE, indicated by a Khorana score of 2 or more. A previous prospective study developed the ONKOTEV score, a 4-variable risk assessment model (RAM) consisting of a Khorana score of more than 2, metastatic disease, vascular or lymphatic compression, and previous VTE event.

OBJECTIVE: To validate the ONKOTEV score as a novel RAM to assess the risk of VTE among outpatients with cancer.

DESIGN, SETTING, AND PARTICIPANTS: ONKOTEV-2 is a noninterventional prognostic study conducted in 3 European centers located in Italy, Germany, and the United Kingdom among a prospective cohort of 425 ambulatory patients with a histologically confirmed diagnosis of a solid tumor who were receiving active treatments. The total study duration was 52 months, with an accrual period of 28 months (from May 1, 2015, to September 30, 2017) and an overall follow up-period of 24 months (data were censored September 30, 2019). Statistical analysis was performed in October 2019.

EXPOSURES: The ONKOTEV score was calculated for each patient at baseline by collecting clinical, laboratory, and imaging data from tests performed for routine practice. Each patient was then observed to detect any thromboembolic event throughout the study period.

MAIN OUTCOMES AND MEASURES: The primary outcome of the study was the incidence of VTE, including deep vein thrombosis and pulmonary embolism.

RESULTS: A total of 425 patients (242 women [56.9%]; median age, 61 years [range, 20-92 years]) were included in the validation cohort of the study. The cumulative incidences for the risk of developing VTE at 6 months were 2.6% (95% CI, 0.7%-6.9%), 9.1% (95% CI, 5.8%-13.2%), 32.3% (95% CI, 21.0%-44.1%), and 19.3% (95% CI, 2.5%-48.0%), respectively, among 425 patients with an ONKOTEV score of 0, 1, 2, and greater than 2 (P < .001). The time-dependent area under the curve at 3, 6, and 12 months was 70.1% (95% CI, 62.1%-78.7%), 72.9% (95% CI, 65.6%-79.1%), and 72.2% (95% CI, 65.2%-77.3%), respectively.

CONCLUSIONS AND RELEVANCE: This study suggests that, because the ONKOTEV score has been validated in this independent study population as a novel predictive RAM for cancer-associated thrombosis, it can be adopted into practice and into clinical interventional trials as a decision-making tool for primary prophylaxis.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Cella CA, Knoedler M, Hall M, et al. Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer. JAMA Netw Open. 2023. PMID: 36795409. doi:10.1001/jamanetworkopen.2023.0010

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。